Rationally-defined microbial consortia suppress multidrug-resistant proinflammatory Enterobacteriaceae via ecological control.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
pubmed:
14
11
2023
medline:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Persistent colonization and outgrowth of pathogenic organisms in the intestine may occur due to long-term antibiotic usage or inflammatory conditions, which perpetuate dysregulated immunity and tissue damage
Identifiants
pubmed: 37961431
doi: 10.21203/rs.3.rs-3462622/v1
pmc: PMC10635318
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK043351
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI172147
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127171
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL157717
Pays : United States
Déclaration de conflit d'intérêts
Competing interests K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL. Y.A., M.U., K.Ama., and Y.K. are employees of JSR corporation. R.J.X. is co-founder of Jnana Therapeutics and Celsius Therapeutics, scientific advisory board member at Nestlé, and board director at MoonLake Immunotherapeutics. J.M.N, and B.O. are employees of Vedanta Biosciences. S.C. was an employee of Vedanta Biosciences at the time of her contributions. All other authors declare no competing interests.